AXIM Biotechnologies, Inc. has entered into an exclusive distribution agreement with VisionPlus Corp. to market and distribute AXIM's TearScan Lactoferrin Test for detecting aqueous-deficient dry eye and TearScan IgE Test for ocular allergy throughout South Korea. This partnership represents a significant expansion of AXIM's diagnostic technology into the Asian market, addressing growing concerns about ocular health conditions in the region.
Under the agreement terms, VisionPlus receives exclusive rights to distribute AXIM's TearScan Lactoferrin and TearScan IgE diagnostic tests across South Korea, both supported by the I-Peak digital reader. The companies will collaborate on Korean MFDS registration, targeting simultaneous submissions for both assays. VisionPlus will lead local compliance, regulatory coordination, and commercialization through its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers. The initial agreement term spans one year with automatic one-year renewals for an additional four years tied to annual sales milestones.
Catalina Valencia, President of AXIM Biotechnologies, emphasized the strategic importance of this partnership, stating that VisionPlus brings exceptional clinical insight and national reach that makes them ideal to introduce AXIM's TearScan platform to South Korea. This collaboration will bring quantitative tear diagnostics directly to clinicians, improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy.
Jerry Park, President of VisionPlus Corp., highlighted the timing of this partnership, noting that years ago VisionPlus recognized that the global rise in digital device use and worsening environmental conditions would lead to an epidemic of Dry Eye Disease. The company established dedicated Dry Eye Clinics across Korea in anticipation of that need. AXIM's TearScan Lactoferrin and IgE tests will complete their vision by creating a one-stop diagnostic and treatment ecosystem for Dry Eye Disease and related conditions.
The TearScan diagnostic portfolio provides quantitative, point-of-care tear biomarker analysis in minutes using a small tear sample. The system's reader delivers precise measurements that help clinicians differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis. This distinction is crucial for selecting effective therapy and monitoring patient progress, addressing a significant challenge in ocular disease management. For more information about AXIM's technology, visit https://www.aximbiotech.com.
This distribution agreement has broader implications for the ophthalmic diagnostics market in Asia, where increasing screen time and environmental factors contribute to rising dry eye disease prevalence. The partnership enables Korean healthcare providers to access advanced diagnostic tools that can improve treatment outcomes and patient satisfaction. By combining AXIM's innovative diagnostic technology with VisionPlus's established clinical network, this collaboration addresses a significant healthcare need while potentially setting a precedent for similar partnerships in other Asian markets facing similar ocular health challenges.
